In Brief: Bristol-Myers Squibb Questran
Executive Summary
Bristol-Myers Squibb Questran: Rx-to-OTC switch for management of hypercholesterolemia likely to be considered at tentatively-scheduled May 13 joint meeting of FDA's Nonprescription Drugs Advisory Committee and Endocrinologic & Metabolic Drugs Advisory Committee. The Questran switch was last discussed at an October 1995 joint meeting...